OptimizeRx Corporation
9.15USD
+0.0700 (+0.77%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on OPRX.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 20 | 32 | 26 | 29 | 22 | 32 | 21 |
| Cost of Revenue | 5 | 5 | 8 | 9 | 11 | 9 | 10 | 8 |
| Gross Profit | 16 | 15 | 24 | 18 | 19 | 13 | 22 | 13 |
| Operating Income | -0 | 0 | 9 | 2 | 3 | -2 | 4 | -9 |
| Net Income | -1 | -0 | 5 | 1 | 2 | -2 | -0 | -9 |
| EPS (Diluted) | -$0.04 | -$0.03 | $0.26 | $0.04 | $0.08 | -$0.12 | $0.00 | -$0.50 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)